Asset Details
Do you wish to reserve the book?
Targeting KRASG13C with cyclic linker based inhibitors to explore warhead orientation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting KRASG13C with cyclic linker based inhibitors to explore warhead orientation
Do you wish to request the book?
Targeting KRASG13C with cyclic linker based inhibitors to explore warhead orientation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting KRASG13C with cyclic linker based inhibitors to explore warhead orientation
2025
Overview
The small GTPase KRAS is a key driver of carcinogenesis when mutated, and significant progress has been made in targeting KRAS
G12C
and other oncogenic variants. Building on our previous work demonstrating the potential of nucleotide-based inhibitors with an acrylamide warhead to target KRAS
G13C
, we designed and synthesized a library of nucleotide-based compounds with cyclic linkers to explore the effect of warhead orientation on reactivity toward Cys13. Using mass spectrometry, kinetic studies, and protein X-ray crystallography, we validated the binding and reactivity of these modulators. In addition, computational predictions of the conformational space of the linkers and warheads provided insights into their reactivity, which agreed well with the experimental data. These findings advance our understanding of the structure-reactivity relationship in these nucleotide-based KRAS inhibitors and will be the basis for further optimization.
